Navigation Links
Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors
Date:12/23/2010

available at http://www.cephalon.com/

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion. Contacts:MediaFritz BittenbenderVice President, Public AffairsT: 610-883-5855C: 610-457-7041fbittenb@cephalon.comChip MerrittVice President, Investor RelationsT: 610-738-6376

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon to Webcast Investor Day
2. Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
3. Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations
4. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
5. Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL
6. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
7. Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc.
8. Cephalon Executive Vice President of Worldwide Pharmaceutical Operations Robert Roche to Resign Position
9. Cephalon Provides Update on Regulatory Review of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
11. Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... -- Cipla, a global pharmaceutical company which uses technology and ... today announced that its UK arm, Cipla EU has ... InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc. The transaction ... $550 million and will be an all cash transaction. ... million for the year ended Dec 2014 and over ...
(Date:9/3/2015)... -- Report Details What can be expected ... to grow at the fastest rates? Visiongain,s brand new ... trends, opportunities and prospects there. Our 205-page ... most lucrative areas in the industry and the future ... sales at overall world market and regional level. You ...
(Date:9/3/2015)... a population of more than 1 billion, China is ... largest potential market for goods and services. In the ... economies in the average rate of growth in real ... an in vitro diagnostics (IVD) market, China trails only ... European countries, and Japan. China represents one of the ...
Breaking Medicine Technology:Cipla to acquire 100% of generic businesses in US for $550M 2Cipla to acquire 100% of generic businesses in US for $550M 3Cipla to acquire 100% of generic businesses in US for $550M 4Cipla to acquire 100% of generic businesses in US for $550M 5Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025: Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4IVD in China 2IVD in China 3IVD in China 4IVD in China 5IVD in China 6IVD in China 7IVD in China 8IVD in China 9IVD in China 10IVD in China 11IVD in China 12IVD in China 13
... MedMined(TM) services from Cardinal Health Equip Hospitals to Measure ... ... Sharing, DUBLIN, Ohio, April 29 Cardinal Health, a,global provider ... care, today announced a new benchmarking tool from,MedMined(TM) services that allows ...
... Opening celebrated with inaugural Symposium on Biofilms, ... 29 ,BASF today announced the official launch ... University. The Advanced Research Initiative at,Harvard University ... specifically to drive new frontiers of scientific,discovery. ...
Cached Medicine Technology:Alabama Hospitals Compare Infection Prevention Performance Statewide With New Benchmarking Tool 2Alabama Hospitals Compare Infection Prevention Performance Statewide With New Benchmarking Tool 3Alabama Hospitals Compare Infection Prevention Performance Statewide With New Benchmarking Tool 4BASF Officially Launches the Collaborative Advanced Research Initiative at Harvard University 2BASF Officially Launches the Collaborative Advanced Research Initiative at Harvard University 3
(Date:9/4/2015)... ... September 04, 2015 , ... The Schmidt National Law Group filed an ... , Schmidt National Law Group, a leading firm in mass-tort litigation, has filed ... Corp., Bayer Essure, Inc., and other Bayer affiliates for injuries alleged to have been ...
(Date:9/4/2015)... ... September 04, 2015 , ... Inmar announced today that ... of its Product, Quality and Manufacturers, Dietary Supplements and Supply Chain Committees. , ... the consumer goods industry, it can be difficult for companies to navigate, stay ...
(Date:9/4/2015)... ... September 04, 2015 , ... “Getting away from the daily stressors ... explore, revitalize and strengthen their ‘couple-ness,’” says Jean Claude Wietzel, general manager at ... Resort Maui, the island’s only Forbes Five Star resort and Travel + Leisure’s No. ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... microbiome taking place in Hollywood, Florida October 9-10, 2015 at the Diplomat Resort ... the 2015 symposium are doctors and researchers at the top of their field ...
(Date:9/4/2015)... ... September 04, 2015 , ... Compliance ... to settlements under the Stark physician self-referral law. “Stark Law DOs and ... from Atlantic Information Services, Inc. (AIS), will detail which deals are attracting the ...
Breaking Medicine News(10 mins):Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2
... care system to make doctors more accountable for their work. ... that the proposal includes various action plans such as increasing the ... a total of 25 members. Various procedures are being introduced which ... into the behavior of doctors. , All this would ...
... may rob an older person of memory and focus, ... big questions seems to be preserved, according to Florida// ... professor of psychology, and Michelle Bourgeois, professor of communication ... University and George Washington University have found that older ...
... Boston and their colleagues have isolated rare cancer stem ... the human disease. ,The leukemia stem ... blood stem cells -- a finding that may be ... them. ,Cancer stem cells are self-renewing cells ...
... Laboratories Ltd today said it had entered into a ... a generic version of Risperidone compressed tablets in the ... between Ranbaxy's wholly owned subsidiary, Ranbaxy Pharmaceuticals Canada Inc ... a statement here., ,"This agreement will provide Ranbaxy ...
... a sign of a skull and crossed bones as well ... health ministry// said Tuesday. ,Every package of cigarette ... a health warning saying "Tobacco Kills" or "Smoking Kills", a ... health message. ,The ministry warned that non-compliance of ...
... product portfolio in the Spanish market, pharma major Ranbaxy Laboratories ... in Spain. // ,Ranbaxy's CEO and MD Malvinder ... the company's M&A strategy to focus on the EU markets., ... Stock Exchange that it continued to see growth opportunities in ...
Cached Medicine News:Health News:Elders with Dementia Can Tap Into Memory Stores to Give Advice 2Health News:Elders with Dementia Can Tap Into Memory Stores to Give Advice 3Health News:Scientists Isolate Leukemia Stem Cells in Mouse Model 2Health News:Scientists Isolate Leukemia Stem Cells in Mouse Model 3
Cushing periosteal elevators, Gutsch handle, sharp, narrow, blade width 3/16" (5 mm), length 7 5/8" (194 mm)....
Lederer periosteal elevators....
Miller Collburn periosteal elevators....
Langebeck periosteal elevators....
Medicine Products: